All forms of epilepsy

Child 1–11 months: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 0.5–1 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary

Child 1–4 years: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 1–3 mg daily, and dose to be taken at night; may be given in 3 divided doses if necessary

Child 5–11 years: Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 3–6 mg daily, and dose to be taken at night; may be given in 3 divided doses if necessary

Child 12–17 years: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, dose usually taken at night; may be given in 3–4 divided doses if necessary

All forms of epilepsy, Myoclonus

Adult: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary

Elderly: Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary

 Panic disorders (with or without agoraphobia) resistant to antidepressant therapy

Adult: 1–2 mg daily

• Current alcohol abuse
• Current drug abuse
• Respiratory depression

Acute porphyrias, airways obstruction, brain damage, cerebellar ataxia depression, spinal ataxia suicidal ideation.

Cautions, Further Information

The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.

Alopecia, bronchial secretion increased (in children), concentration impaired, coordination abnormal drooling (in children), gastrointestinal disorder, Hyper salivation (in children), incomplete precocious puberty (in children), increased risk of fall (in adults), increased risk of fracture (in adults), muscle tone decreased, nystagmus, psychotic disorder, seizures, sexual dysfunction, skin reactions, speech impairment, suicidal behaviours, urinary incontinence.

Breast Feeding Present in milk, and should be avoided if possible during breast-feeding, monitoring all infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.

Store in a cool and dry place

Clonaz 0.25: 10×15 Tablets

Clonaz 0.5: 20×15 Tablets

Monitoring Requirements

In children routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals, however, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity, similarly, haematological and biochemical monitoring should not be uNdertaken unless clinically indicated.